Some low-quality evidence has shown that IVIG may be beneficial for patients with refractory POTS by neutralising pathogenic auto-antibodies.[1]Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health expert consensus meeting - part 1. Auton Neurosci. 2021 Nov;235:102828.
https://www.doi.org/10.1016/j.autneu.2021.102828
http://www.ncbi.nlm.nih.gov/pubmed/34144933?tool=bestpractice.com
[77]Schofield JR, Chemali KR. Intravenous immunoglobulin therapy in refractory autoimmune dysautonomias: a retrospective analysis of 38 patients. Am J Ther. 2019 Sep/Oct;26(5):570-82.
http://www.ncbi.nlm.nih.gov/pubmed/29781817?tool=bestpractice.com
[78]Goodman BP. Treatment updates in postural tachycardia syndrome. Curr Treat Options Neurol. 2020 Aug 25;22:35.
https://link.springer.com/article/10.1007/s11940-020-00643-3
[79]ClinicalTrials.gov. IVIG (Gamunex-C) treatment study for POTS subjects (iSTAND). Jan 2023 [internet publication].
https://clinicaltrials.gov/ct2/show/study/NCT03919773